Antares Pharma Inc (ATRS) Return on Equity ROE from the first quarter 2022 to first quarter 2021 and annually, average high and low, overall ranking from Mar 31 2022 to Mar 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Antares Pharma Inc   (NASDAQ: ATRS)

Antares Pharma Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Antares Pharma Inc in the first quarter 2022?
Antares Pharma Inc achieved a return on average equity (ROE) of 25.74 % in its first quarter 2022, this is above ATRS's average return on equity of -19.79%.
Antares Pharma Inc shareholder's equity over the 12 months ending in its first quarter 2022 are valued at $156 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Medical Equipment & Supplies industry 13 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2021 from 529 to 696.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter
Y / Y Equity Change 39.25 % 47.55 % 115.86 % 130.3 % -
Y / Y Net Income Change - -36.4 % 7.95 % 103.22 % -
Net Income (TTM) in Millions 40 46 65 65 62
Return On Equity (TTM) 25.74 % 32.21 % 50.17 % 58.38 % 67.79 %
ATRS's Total Ranking # 696 # 529 # 278 # 243 # 151
Equity (TTM) in Millions 176 176 141 132 126
Seq. Equity Change 0.01 % 24.8 % 6.67 % 4.6 % 5.97 %
Seq. Net Income Change - 506.03 % 22.01 % 16.53 % -92.62 %

Back to ATRS Management Effectiveness >> ATRS's 5 Years Annual ROE >> Compare ATRS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 14
Sector # 73
Overall # 696

Return On Equity Statistics
High Average Low
76.08 %
-19.79 %
-72.77 %
(Dec 31 2020)   (Mar 31 2015)





ATRS Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Equity in Millions 176 119 55 39 34
Y / Y Equity Change 47.55 % 118.56 % 39.74 % 16.26 % -25.81 %
Net Income in Millions 46 56 -2 -7 -17
Y / Y Net Income Change -17.64 % - - - -
Return On Equity 26.34 % 47.18 % -3.72 % -16.7 % -49.91 %

Back to ATRS Management Effectiveness >> ATRS's 5 Years Annual ROE >> Compare ATRS ROE to its Competitors




Annual Roe Comment
In 2021 ROE decreased compared to the previous year to 26.34 %, due to deterioration of net income.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ATRS's' Return on Equity at Yahoo Finance
ATRS's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ATRS's Competitors
Subscribers only: Roe for Antares Pharma Inc 's Suppliers
Subscribers only: Return On Equity for ATRS's Customers




Companies with similar Return On Equity at Mar 31 2022, within Healthcare Sector ROE
Dynavax Technologies Corporation  65.79 %
Iteos Therapeutics Inc   64.68 %
Vivos Therapeutics Inc   63.60 %
Innoviva Inc   60.50 %
Uniqure N v   54.85 %
Quidelortho Corp  54.46 %
Cryo cell International Inc   51.56 %
Retractable Technologies Inc  50.99 %
Siga Technologies Inc  49.46 %
Zoetis Inc   45.41 %
Nrc Health  45.08 %
Reflect Scientific Inc  44.88 %
Regeneron Pharmaceuticals Inc   44.65 %
Elite Pharmaceuticals Inc   44.17 %
Integrated Biopharma Inc  44.01 %
Fulgent Genetics Inc   41.32 %
Hanger inc.  40.13 %
Organogenesis Holdings Inc   39.59 %
Merck and Co Inc   38.23 %
3m Company  37.89 %
Chemed Corporation  36.36 %
Silo Pharma Inc  35.91 %
Hologic Inc  35.62 %
Semler Scientific inc   35.14 %
Co diagnostics Inc   34.47 %
Biocept Inc   34.23 %
Pfizer Inc  32.65 %
Prophase Labs Inc   32.04 %
Exelixis Inc   31.29 %
Quest Diagnostics Inc  31.07 %

Date modified: 2026-09-08T15:10:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.